Literature DB >> 21305379

In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells.

Shicheng Yang1, Luca Gattinoni, Gattinoni Luca, Fang Liu, Yun Ji, Zhiya Yu, Nicholas P Restifo, Steven A Rosenberg, Richard A Morgan.   

Abstract

The T-lymphocyte pool can be subdivided into naïve (Tn), effector memory (Tem), and central memory (Tcm) T cells. In this study, we characterized in vitro short-term cultured anti-tumor human T lymphocytes generated by lentiviral transduction with an anti-tumor antigen TCR vector. Within 2 weeks of in vitro culture, the cultured T cells showed a Tcm-like phenotype illustrated by a high percentage of CD62L and CD45RO cells. When the cells were sorted into populations that were CD45RO+/CD62L-(Tem), CD45RO+/CD62L+(Tcm), or CD45RO(low)/CD62L+(Tn) and co-cultured with antigen-matched tumor lines, the magnitude of cytokine release from these populations for IFNγ (Tn < Tcm < Tem) and IL-2 (Tn > Tcm > Tem) mimicked the types of immune cell responses observed in vivo. In comparing cell-mediated effector function, Tn were found to be deficient (relative to Tcm and Tem) in the ability to form conjugates with tumor cells and subsequent lytic activity. Moreover, analysis of the gene expression profiles of the in vitro cultured and sorted T-cell populations also demonstrated patterns consistent with their in vivo counterparts. When Tcm and Tem were tested for the ability to survive in vivo, Tcm displayed significantly increased engraftment and persistence in NOD/SCID/γc(-/-) mice. In general, a large percentage of in vitro generated anti-tumor T lymphocytes mimic a Tcm-like phenotype (based on phenotype, effector function, and increased persistence in vivo), which suggests that these Tcm-like cultured T cells may be optimal for adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21305379      PMCID: PMC3080434          DOI: 10.1007/s00262-011-0977-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  51 in total

1.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

2.  Molecular identification of a novel family of human Ig superfamily members that possess immunoreceptor tyrosine-based inhibition motifs and homology to the mouse gp49B1 inhibitory receptor.

Authors:  J P Arm; C Nwankwo; K F Austen
Journal:  J Immunol       Date:  1997-09-01       Impact factor: 5.422

3.  Lineage relationship and protective immunity of memory CD8 T cell subsets.

Authors:  E John Wherry; Volker Teichgräber; Todd C Becker; David Masopust; Susan M Kaech; Rustom Antia; Ulrich H von Andrian; Rafi Ahmed
Journal:  Nat Immunol       Date:  2003-02-03       Impact factor: 25.606

4.  Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules.

Authors:  Megan M Suhoski; Tatiana N Golovina; Nicole A Aqui; Victoria C Tai; Angel Varela-Rohena; Michael C Milone; Richard G Carroll; James L Riley; Carl H June
Journal:  Mol Ther       Date:  2007-03-20       Impact factor: 11.454

5.  Id2 is critical for cellular proliferation and is the oncogenic effector of N-myc in human neuroblastoma.

Authors:  Anna Lasorella; Renata Boldrini; Carlo Dominici; Alberto Donfrancesco; Yoshifumi Yokota; Alessandro Inserra; Antonio Iavarone
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

6.  CCR7 expression and memory T cell diversity in humans.

Authors:  J J Campbell; K E Murphy; E J Kunkel; C E Brightling; D Soler; Z Shen; J Boisvert; H B Greenberg; M A Vierra; S B Goodman; M C Genovese; A J Wardlaw; E C Butcher; L Wu
Journal:  J Immunol       Date:  2001-01-15       Impact factor: 5.422

7.  Finishing the euchromatic sequence of the human genome.

Authors: 
Journal:  Nature       Date:  2004-10-21       Impact factor: 49.962

8.  Commitment point during G0-->G1 that controls entry into the cell cycle.

Authors:  Nicholas C Lea; Stephen J Orr; Kai Stoeber; Gareth H Williams; Eric W-F Lam; Mohammad A A Ibrahim; Ghulam J Mufti; N Shaun B Thomas
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

Review 9.  Central memory and effector memory T cell subsets: function, generation, and maintenance.

Authors:  Federica Sallusto; Jens Geginat; Antonio Lanzavecchia
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

10.  A T-cell specific TCR delta DNA binding protein is a member of the human GATA family.

Authors:  V Joulin; D Bories; J F Eléouet; M C Labastie; S Chrétien; M G Mattéi; P H Roméo
Journal:  EMBO J       Date:  1991-07       Impact factor: 11.598

View more
  24 in total

1.  Neutrophil-Derived Myeloperoxidase Facilitates Both the Induction and Elicitation Phases of Contact Hypersensitivity.

Authors:  Anna Strzepa; Cody J Gurski; Landon J Dittel; Marian Szczepanik; Kirkwood A Pritchard; Bonnie N Dittel
Journal:  Front Immunol       Date:  2021-01-25       Impact factor: 7.561

2.  Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15.

Authors:  Yang Xu; Ming Zhang; Carlos A Ramos; April Durett; Enli Liu; Olga Dakhova; Hao Liu; Chad J Creighton; Adrian P Gee; Helen E Heslop; Cliona M Rooney; Barbara Savoldo; Gianpietro Dotti
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

3.  Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer.

Authors:  H Fujiwara; T Ochi; F Ochi; Y Miyazaki; H Asai; M Narita; S Okamoto; J Mineno; K Kuzushima; H Shiku; M Yasukawa
Journal:  Leukemia       Date:  2015-06-24       Impact factor: 11.528

4.  Enhanced local and systemic anti-melanoma CD8+ T cell responses after memory T cell-based adoptive immunotherapy in mice.

Authors:  Amanda Contreras; Siddhartha Sen; Andrew J Tatar; David A Mahvi; Justin V Meyers; Prakrithi Srinand; Marulasiddappa Suresh; Clifford S Cho
Journal:  Cancer Immunol Immunother       Date:  2016-03-24       Impact factor: 6.968

Review 5.  Human cell-based artificial antigen-presenting cells for cancer immunotherapy.

Authors:  Marcus O Butler; Naoto Hirano
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

6.  Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails.

Authors:  Shicheng Yang; Yun Ji; Luca Gattinoni; Ling Zhang; Zhiya Yu; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Cancer Immunol Immunother       Date:  2012-12-04       Impact factor: 6.968

7.  A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.

Authors:  Shicheng Yang; Gary E Archer; Catherine E Flores; Duane A Mitchell; John H Sampson
Journal:  Cancer Immunol Immunother       Date:  2013-08-27       Impact factor: 6.968

8.  Antitumor effects and persistence of a novel HER2 CAR T cells directed to gastric cancer in preclinical models.

Authors:  Yali Han; Chuanyong Liu; Guanhua Li; Juan Li; Xingyan Lv; Huan Shi; Jie Liu; Shuai Liu; Peng Yan; Shuyun Wang; Yuping Sun; Meili Sun
Journal:  Am J Cancer Res       Date:  2018-01-01       Impact factor: 6.166

Review 9.  T-cell receptor gene therapy--ready to go viral?

Authors:  Terhi Karpanen; Johanna Olweus
Journal:  Mol Oncol       Date:  2015-10-20       Impact factor: 6.603

10.  How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer.

Authors:  Inbal Daniel-Meshulam; Shlomo Ya'akobi; Chen Ankri; Cyrille J Cohen
Journal:  Front Immunol       Date:  2012-07-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.